Cerebrolysin 60mg Research Peptide Complex
Cerebrolysin is a peptide complex consisting of low molecular weight peptides and amino acids commonly utilized in laboratory research involving neuronal signaling, cellular communication, and neurotropic pathway investigations.
This product is intended strictly for laboratory research purposes, not for human consumption, therapeutic use, veterinary use, or diagnostic use.
Specifications
| Compound | Cerebrolysin 60 mg |
|---|---|
| Category | Peptide |
| SKU | GRL-Cerebrolysin-60mg |
| Unit size | 60 mg |
| Price | $50.00 |
| Availability | In stock |
| Intended use | Laboratory research use only |
Cerebrolysin 60 mg is also written Cerebrolysin peptide.
Research Applications
- Neurotropic signaling research
- Neuronal communication studies
- Cellular response investigations
- Peptide interaction research
- Laboratory-based biological studies
Product Specifications
- Contents: Cerebrolysin peptide complex
- Quantity: 60mg
- Appearance: Lyophilized powder
- Storage: Refrigerate upon receipt
Research questions about this compound
What is the evidence grade for Cerebrolysin?
The evidence for Cerebrolysin is primarily based on human clinical trials, specifically randomized, placebo-controlled studies focused on acute stroke recovery , . These represent a high level of clinical evidence for the specific conditions studied, though they do not provide evidence for other applications.
Does Cerebrolysin improve memory in healthy individuals?
The cited research does not examine the effects of Cerebrolysin on memory in healthy individuals , . All available human data provided in these sources are restricted to patients recovering from acute ischemic stroke , .
Is Cerebrolysin effective for neurodegenerative diseases?
The cited research focuses exclusively on acute ischemic stroke , . There is no data provided in these sources regarding the efficacy or safety of the compound for chronic neurodegenerative conditions.
How long do the effects of Cerebrolysin last?
The cited trials observed participants over defined periods, such as 21 days in the acute stroke study . The research does not provide data on the duration of effects beyond the observation windows defined in these specific clinical trials , .
labels, lab notebooks, reorders
Compare CJC-1295 (No DAC) + Ipamorelin 10mg and Cerebrolysin 60 mg catalog facts →
